Pacer Advisors
TCRT icon

Pacer Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Pacer Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-84
Closed -$45K – 1552
2021
Q1 		$45K Buy
84
+9
+12% +$5.6K ﹤0.01% 1452
2020
Q4 		$28K Buy
75
+28
+60% +$11.1K ﹤0.01% 1467
2020
Q3 		$18K Buy
+47
New +$20.8K ﹤0.01% 1358
2018
Q4 		– Sell
-74
Closed -$35K – 983
2018
Q3 		$35K Buy
+74
New +$31.7K ﹤0.01% 1158
2018
Q1 		– Sell
-20
Closed -$12K – 1126
2017
Q4 		$12K Buy
+20
New +$14.4K ﹤0.01% 1133

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Pacer Advisors's TCRT Position: Q2 2021 in Review

Pacer Advisors sold out of Alaunos Therapeutics (TCRT) in Q2 2021, closing a stake of 84 shares — an estimated $45K sold.

Pacer Advisors first reported a position in TCRT in Q4 2017 and held it in 5 quarters. The position peaked at $45K in Q1 2021. 155 funds tracked by Wall St. Rank hold TCRT as of Q2 2021.

  • Pacer Advisors reported no remaining Alaunos Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 84 Alaunos Therapeutics shares in Q2 2021, an estimated $45K.
  • Pacer Advisors first reported a position in Alaunos Therapeutics in Q4 2017 and held it in 5 quarters.
  • Pacer Advisors's Alaunos Therapeutics position peaked at $45K in Q1 2021.
  • 155 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.